Yelena V Kovtun

Summary

Affiliation: ImmunoGen Inc
Country: USA

Publications

  1. ncbi Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
    Yelena V Kovtun
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:3214-21. 2006
  2. ncbi Cell killing by antibody-drug conjugates
    Yelena V Kovtun
    ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139 4239, USA
    Cancer Lett 255:232-40. 2007
  3. ncbi Antibody-maytansinoid conjugates designed to bypass multidrug resistance
    Yelena V Kovtun
    ImmunoGen, Inc, Waltham, Massachusetts 02451, USA
    Cancer Res 70:2528-37. 2010
  4. ncbi Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
    Hans K Erickson
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:4426-33. 2006
  5. ncbi Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
    Victor S Goldmacher
    ImmunoGen, Inc, 830 Winter Street, Waltham, MA 02451 1477, USA
    Ther Deliv 2:397-416. 2011

Detail Information

Publications5

  1. ncbi Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
    Yelena V Kovtun
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:3214-21. 2006
    ..Our data offer a rationale for developing optimally constructed antibody-drug conjugates for treating tumors that express the target antigen either in a homogeneous or heterogeneous manner...
  2. ncbi Cell killing by antibody-drug conjugates
    Yelena V Kovtun
    ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139 4239, USA
    Cancer Lett 255:232-40. 2007
    ..This review summarizes the current knowledge of the mechanisms of killing of antigen-expressing and bystander cells by antibody-drug conjugates...
  3. ncbi Antibody-maytansinoid conjugates designed to bypass multidrug resistance
    Yelena V Kovtun
    ImmunoGen, Inc, Waltham, Massachusetts 02451, USA
    Cancer Res 70:2528-37. 2010
    ..This study points the way to the development of ADCs that bypass multidrug resistance...
  4. ncbi Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
    Hans K Erickson
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:4426-33. 2006
    ....
  5. ncbi Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
    Victor S Goldmacher
    ImmunoGen, Inc, 830 Winter Street, Waltham, MA 02451 1477, USA
    Ther Deliv 2:397-416. 2011
    ..In this article, we will review the considerations for selecting a target antigen, the design of the conjugate, and the pre-clinical and clinical experiences with the current generation of antibody-drug conjugates...